Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dextran→

Dextran Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9004-54-0
Molecular formula
Not available
Molecular weight
Not available
Drug class
Branched glucose polysaccharideplasma volume expander and pharmaceutical polymer
Mechanism of action
High-molecular-weight dextran acts as a colloid osmotic agent in the intravascular compartment, expanding plasma volume. Lower molecular-weight dextrans have additional effects on blood rheology and platelet/coagulation interactions.
Indications / reported uses
  • Historical use as an intravenous plasma volume expander in selected settings; use is restricted or uncommon due to anaphylaxis, renal and coagulation risks. Other dextran grades are used as excipients or in diagnostic products and should not be treated as therapeutic substitutes.

Sources: NLM MeSH — Dextran · PubMed — Dextran plasma expander safety · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dextran Environmental Risk Assessment (ERA) (the Dextran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.